ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
ARWR$49.00-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except per share amounts)
| March 31, 2026 | September 30, 2025 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash, cash equivalents and restricted cash | $147,531 | $88,706 |
| Cash at variable interest entity | 40,986 | 137,842 |
| Accounts receivable | 15,685 | 6,824 |
| Available-for-sale securities, at fair value and short-term investments | 1,595,574 | 692,818 |
| Prepaid expenses | 21,721 | 10,933 |
| Other current assets | 18,254 | 13,516 |
| Total current assets | 1,839,751 | 950,639 |
| Property, plant and equipment, net | 374,822 | 382,515 |
| Intangible assets, net | 6,011 | 6,861 |
| Right-of-use assets | 42,794 | 43,891 |
| Other assets | 4,887 | 1,389 |
| Total Assets | $2,268,265 | $1,385,295 |
| LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 30,747 | $17,674 |
| Accrued expenses | 76,585 | 90,419 |
| Accrued payroll and benefits | 20,366 | 26,895 |
| Lease liabilities | 7,774 | 7,289 |
| Deferred revenue | 108,543 | 2,399 |
| Credit facility | 40,000 | 40,000 |
| Other liabilities | 11,205 | 10,811 |
| Total current liabilities | 295,220 | 195,487 |
| Long-term liabilities: | ||
| Lease liabilities, net of current portion | 100,106 | 104,112 |
| Deferred revenue, net of current portion | 48,615 | — |
| Liability related to the sale of future royalties | 383,829 | 367,397 |
| Credit facility, net of current portion | 159,639 | 214,883 |
| Convertible notes, net | 681,940 | — |
| Total long-term liabilities | 1,374,129 | 686,392 |
| Commitments and contingencies (Note 7) | ||
| Noncontrolling interest and stockholders’ equity: | ||
| Common stock, $0.001 par value:Authorized 290,000 shares; 143,232 shares issued and 140,571 outstanding as of March 31, 2026 and 138,363 shares issued and 135,702 outstanding as of September 30, 2025 | 236 | 231 |
| Additional paid-in capital | 2,395,267 | 2,139,725 |
| Accumulated other comprehensive income | 742 | 6,443 |
| Accumulated deficit | (1,729,075) | (1,627,154) |
| Treasury stock; at cost; 2,661 shares of common stock at March 31, 2026 and September 30, 2025 | (53,193) | (53,193) |
| Stockholders’ equity | 613,977 | 466,052 |
| Noncontrolling interest | (15,061) | 37,364 |
| Total noncontrolling interest and stockholders’ equity | 598,916 | 503,416 |
| Total Liabilities, Noncontrolling Interest and Stockholders’ Equity | $2,268,265 | $1,385,295 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.